Celularity and DefEYE entered into a strategic partnership that includes a $12 million investment in DefEYE’s Series Seed Preferred Equity round and an exclusive sublicense of Celularity’s ophthalmic biologics portfolio.
The portfolio covers Biovance, Biovance 3L, Interfyl, and CentaFlex, all decellularized biologic solutions for eye care. Celularity will serve as the exclusive contract manufacturer for these products, enabling DefEYE to scale production.
The agreement grants Celularity the right to appoint one member to DefEYE’s five‑member board, strengthening governance ties. DefEYE, which launched as an independent company on Oct 1, 2025, previously operated as Verséa Ophthalmics and reported a 70% sales increase in 2024.
Celularity, a regenerative medicine company focused on placental‑derived therapies, has faced Nasdaq compliance issues in the past but has since filed its reports and regained compliance. The partnership expands Celularity’s commercial reach into the ophthalmic segment, which is expected to contribute to its revenue mix beyond its existing cancer and immunology pipelines.
Management highlighted that the collaboration leverages Celularity’s manufacturing expertise and the growing demand for decellularized biologics in ophthalmology, positioning both companies to capture a larger share of the eye‑care market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.